Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report)’s share price rose 7.9% on Monday . The company traded as high as $1.52 and last traded at $1.50. Approximately 14,350 shares traded hands during trading, a decline of 50% from the average daily volume of 28,826 shares. The stock had previously closed at $1.39.
Humacyte Stock Up 7.9 %
The company has a 50 day moving average of $1.76 and a 200-day moving average of $1.99.
Humacyte Company Profile
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
See Also
- Five stocks we like better than Humacyte
- How Investors Can Find the Best Cheap Dividend Stocks
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- What Are Earnings Reports?
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- What is Insider Trading? What You Can Learn from Insider Trading
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
